Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
211. |
ECCT/15/06/03 | DolutegrAvir With NRTIs as second-line treatment (DAWNING) A Phase 3b, randomised, open-label study of the antiviral activity and safety of dolutegravir compared to lopinavir/ritonavir both administered with dual nucleoside reverse transcriptase inhibitor therapy in HIV-1 infected adult subjects with treatment failure on first line therapy |
Principal Investigator(s) 1. Dr. Evans Inyangala Amukoye 2. Dr. Maricianah Atieno Onono Site(s) in Kenya 1. Center for Respiratory Diseases Research, CRDR, KEMRI, Nairobi (Nairobi City county) 2. KEMRI-Research Care and Training Program (RCTP), Family AIDS Care and Education Services (FACES), Lumumba health centre (Kisumu county) |
29-07-2015 |
View |
212. |
ECCT/15/01/05 | In vivo efficacies of AL and DP Open label randomized study evaluating the in vivo efficacies of Artemether-lumefantrine and Dihydroartemisinin-piperaquine in the treatment of uncomplicated Plasmodium falciparum malaria in children under five years of age in western Kenya. |
Principal Investigator(s) 1. AAron Samuels 2. Simon Kariuki Site(s) in Kenya Siaya District Hospital |
03-03-2015 |
View |
213. |
ECCT/14/09/04 | Assessment of Safety and Efficacy of Brozedex Syrup in the Treatment of Productive Cough. Phase III, Randomized, Double Blind, Placebo-Controlled, Parallel Group and Multi-Site Study Conducted In Nairobi in three sites |
Principal Investigator(s) 1. Hudson Aubrey Lodenyo Site(s) in Kenya 1. Rhodes Clinic/Ngaira Health Centre (Nairobi City county) 2. Mbagathi District Hospital (Nairobi City county) 3. Mama Lucy Hospital (Nairobi City county) |
09-12-2014 |
View |
214. |
ECCT/14/10/02 | Acronymn: CRASH-3 Short Title: Clinical Randomisation of an Antifibrinolytic in Significant Head Injury Full Title: Tranexamic acid for the treatment of significant traumatic brain injury: an international randomised, double blind placebo controlled trial ISRCTN15088122 ClinicalTrials.gov ID: NCT01402882 |
Principal Investigator(s) 1. Kiboi Githinji Julius 2. Dullo Michael 3. Lallet Tasneem Essaji Site(s) in Kenya 1. Kenyatta National Hospital (Nairobi City county) 2. Kitui District Hospital (Kitui county) 3. The Nairobi Hospital (Nairobi City county) |
05-02-2015 |
View |
215. |
ECCT/14/09/02 | LIVING STUDY-PHASE III B. Prospective study of Lopinavir based ART for HIVInfected childreNGlobally (LIVING study) |
Principal Investigator(s) 1. Elizabeth Maleche Obimbo 2. Elizabeth Bukusi 3. Winstone Nyandiko 4. Bienvenu Baruani Ngoy 5. Joseph Kariuki Mbuthia 6. Allan Godfrey Otieno 7. Lucy Koech 8. Neema Mturi 9. Beatrice Mutai Site(s) in Kenya 1. University of Nairobi/ Kenyatta National Hospital (Nairobi City county) 2. AMPATH, Moi University Teaching and Referral Hospital Eldoret (Uasin Gishu county) 3. MSF Belgium Kibera Clinic (Nairobi City county) 4. Gertrude\'s Children\'s Hospital (Nairobi City county) 5. Mbagathi District Hospital (Nairobi City county) |
08-12-2014 |
View |
216. |
ECCT/14/09/01 | Extension to study MALARIA-055 PRI (110021) for evaluation of long-term efficacy, safety and immunogenicity of GSK Biologicals’candidate malaria vaccine (SB257049) in infants and children in Africa An open extension to the phase III, multi-center study MALARIA-055 PRI (110021) to evaluate long-term efficacy, safety and immunogenicity of the RTS,S/AS01E candidate vaccine against malaria disease caused by Plasmodium falciparum in infants and children in Africa. Study number: MALARIA-076 (200599) |
Principal Investigator(s) 1. Walter Otieno Site(s) in Kenya Kenya Medical Research Institute/Walter Reed Project |
23-09-2015 |
View |
217. |
ECCT/14/08/02 | A5288 Management Using the Latest Technologies in Resource-limited Settings to Optimize Combination Therapy After Viral Failure (MULTI-OCTAVE) |
Principal Investigator(s) 1. ESTHER MUMBI MAKANGA Site(s) in Kenya KEMRI/CDC CLINICAL RESEARCH CENTRE |
08-09-2014 |
View |
218. |
ECCT/14/08/03 | STAND Study (Shortening Treatment by Advancing Novel Drugs) Long Title: A Phase 3 Open Label Partially Randomised Trial to Evaluate the Efficacy, Safety and Tolerability of the Combination of Moxifloxacin plus PA-824 plus Pyrazinamide after 4 and 6 months of Treatment in Adult Subjects with Drug Sensitive Smear Positive Pulmonary Tuberculosis and after 6 months of Treatment in Adult Subjects with Multi-Drug Resistant, Smear-Positive Pulmonary Tuberculosis Short Title: STAND Study (Shortening Treatment by Advancing Novel Drugs) |
Principal Investigator(s) 1. Dr Videlis Nduba 2. Dr Evans Amukoye Site(s) in Kenya 1. KEMRI-CRDR(East Nairobi) (Nairobi City county) 2. KEMRI-CRDR(West Nairobi) (Nairobi City county) |
17-08-2015 |
View |
219. |
ECCT/14/06/01 | ACTG -5279 Phase III Clinical Trial of Ultra-Short-Course Rifapentine/Isoniazid for the Prevention of Active Tuberculosis in HIV-Infected Individuals with Latent Tuberculosis Infection |
Principal Investigator(s) 1. Dr. Kevin N/A Cain Site(s) in Kenya 1. KEMRI/WRP CRS (Kericho county) 2. Moi University Clinical Research Center CRS ()12601 (Uasin Gishu county) |
30-06-2014 |
View |
220. |
ECCT/12/03/01 | Role of Fish Oil Omega-3 Fatty Acids on Depression among HIV-Seropositive Pregnant Women in Nairobi: A Randomized Double-blind Controlled Trial |
Principal Investigator(s) 1. Rose Okoyo Opiyo Site(s) in Kenya 1. Riruta Health Centre (Nairobi City county) 2. Kariobangi North Health Centre (Nairobi City county) 3. Mathare North Health Centre (Nairobi City county) 4. Kayole II Sub-district hospital (Nairobi City county) |
22-05-2012 |
View |
